B7-H3, an immune checkpoint glycoprotein, facilitates immune evasion and the promotion of tumors and is highly expressed on the surface of prostate cancer (PCa) cells, which makes it a feasible and robust candidate for immunotherapies against advanced prostate cancer. Here, we summarize and discuss recent findings on the suitability of targeting B7-H3 in PCa treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.trecan.2024.05.003 | DOI Listing |
Publication Analysis
Top Keywords
prostate cancer
12
b7-h3 robust
4
robust target
4
target immunotherapy
4
immunotherapy prostate
4
cancer b7-h3
4
b7-h3 immune
4
immune checkpoint
4
checkpoint glycoprotein
4
glycoprotein facilitates
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!